Skip to main content
NCBI home page
Heart logoLink to Heart
. 1996 Nov;76(3 Suppl 3):92–97. doi: 10.1136/hrt.76.3_suppl_3.92

Hypertension, hypertrophy, heart failure

M Gary Nicholls 1
PMCID: PMC484495  PMID: 8983668

Full text

PDF
92

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agabiti-Rosei E., Ambrosioni E., Dal Palù C., Muiesan M. L., Zanchetti A. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens. 1995 Nov;13(11):1325–1334. doi: 10.1097/00004872-199511000-00015. [DOI] [PubMed] [Google Scholar]
  2. Alexander M., Grumbach K., Selby J., Brown A. F., Washington E. Hospitalization for congestive heart failure. Explaining racial differences. JAMA. 1995 Oct 4;274(13):1037–1042. [PubMed] [Google Scholar]
  3. Amery A., Birkenhäger W., Brixko P., Bulpitt C., Clement D., Deruyttere M., De Schaepdryver A., Dollery C., Fagard R., Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985 Jun 15;1(8442):1349–1354. doi: 10.1016/s0140-6736(85)91783-0. [DOI] [PubMed] [Google Scholar]
  4. Anderson K. P. Sudden death, hypertension, and hypertrophy. J Cardiovasc Pharmacol. 1984;6 (Suppl 3):S498–S503. [PubMed] [Google Scholar]
  5. Andersson B., Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J. 1993 Sep;126(3 Pt 1):632–640. doi: 10.1016/0002-8703(93)90414-5. [DOI] [PubMed] [Google Scholar]
  6. Bikkina M., Larson M. G., Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol. 1993 Oct;22(4):1111–1116. doi: 10.1016/0735-1097(93)90424-y. [DOI] [PubMed] [Google Scholar]
  7. Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. doi: 10.1016/0140-6736(90)90944-z. [DOI] [PubMed] [Google Scholar]
  8. Dahlöf B., Lindholm L. H., Hansson L., Scherstén B., Ekbom T., Wester P. O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991 Nov 23;338(8778):1281–1285. doi: 10.1016/0140-6736(91)92589-t. [DOI] [PubMed] [Google Scholar]
  9. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992 Feb;5(2):95–110. doi: 10.1093/ajh/5.2.95. [DOI] [PubMed] [Google Scholar]
  10. Devereux R. B., Dahlof B. Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994 Oct;8(10):735–739. [PubMed] [Google Scholar]
  11. Doughty R., Yee T., Sharpe N., MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. N Z Med J. 1995 Nov 24;108(1012):473–475. [PubMed] [Google Scholar]
  12. Doyle A. E. Does hypertension predispose to coronary disease? Conflicting epidemiological and experimental evidence. Am J Hypertens. 1988 Jul;1(3 Pt 1):319–324. doi: 10.1093/ajh/1.3.319. [DOI] [PubMed] [Google Scholar]
  13. Drizd T., Dannenberg A. L., Engel A. Blood pressure levels in persons 18-74 years of age in 1976-80, and trends in blood pressure from 1960 to 1980 in the United States. Vital Health Stat 11. 1986 Jul;(234):1–68. [PubMed] [Google Scholar]
  14. Eriksson H. Heart failure: a growing public health problem. J Intern Med. 1995 Feb;237(2):135–141. doi: 10.1111/j.1365-2796.1995.tb01153.x. [DOI] [PubMed] [Google Scholar]
  15. Eriksson H., Svärdsudd K., Caidahl K., Bjurö T., Larsson B., Welin L., Ohlson L. O., Wilhelmsen L. Early heart failure in the population. The study of men born in 1913. Acta Med Scand. 1988;223(3):197–209. doi: 10.1111/j.0954-6820.1988.tb15788.x. [DOI] [PubMed] [Google Scholar]
  16. Frohlich E. D., Apstein C., Chobanian A. V., Devereux R. B., Dustan H. P., Dzau V., Fauad-Tarazi F., Horan M. J., Marcus M., Massie B. The heart in hypertension. N Engl J Med. 1992 Oct 1;327(14):998–1008. doi: 10.1056/NEJM199210013271406. [DOI] [PubMed] [Google Scholar]
  17. Gaudron P., Eilles C., Kugler I., Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993 Mar;87(3):755–763. doi: 10.1161/01.cir.87.3.755. [DOI] [PubMed] [Google Scholar]
  18. Ghali J. K., Cooper R., Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med. 1990 Apr;150(4):769–773. [PubMed] [Google Scholar]
  19. Ghali J. K., Kadakia S., Cooper R. S., Liao Y. L. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol. 1991 May;17(6):1277–1282. doi: 10.1016/s0735-1097(10)80135-4. [DOI] [PubMed] [Google Scholar]
  20. Hansson L. Does drug treatment improve survival in mild-to-moderate hypertension? J Hypertens. 1995 Nov;13(11):1354–1355. doi: 10.1097/00004872-199511000-00019. [DOI] [PubMed] [Google Scholar]
  21. Ho K. K., Anderson K. M., Kannel W. B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993 Jul;88(1):107–115. doi: 10.1161/01.cir.88.1.107. [DOI] [PubMed] [Google Scholar]
  22. Iwasaki K., Kusachi S., Hina K., Yamasaki S., Kita T., Endo C., Tsuji T. Q-wave regression unrelated to patency of infarct-related artery or left ventricular ejection fraction or volume after anterior wall acute myocardial infarction treated with or without reperfusion therapy. Am J Cardiol. 1995 Jul 1;76(1):14–20. doi: 10.1016/s0002-9149(99)80793-0. [DOI] [PubMed] [Google Scholar]
  23. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995 Mar;7(3):242–250. doi: 10.2165/00019053-199507030-00008. [DOI] [PubMed] [Google Scholar]
  24. Johannesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy. 1994 Mar;28(1):1–13. doi: 10.1016/0168-8510(94)90016-7. [DOI] [PubMed] [Google Scholar]
  25. Kannel W. B., Abbott R. D., Savage D. D., McNamara P. M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982 Apr 29;306(17):1018–1022. doi: 10.1056/NEJM198204293061703. [DOI] [PubMed] [Google Scholar]
  26. Kannel W. B., Castelli W. P., McNamara P. M., McKee P. A., Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972 Oct 19;287(16):781–787. doi: 10.1056/NEJM197210192871601. [DOI] [PubMed] [Google Scholar]
  27. Kannel W. B., Dannenberg A. L., Abbott R. D. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J. 1985 Mar;109(3 Pt 1):581–585. doi: 10.1016/0002-8703(85)90566-6. [DOI] [PubMed] [Google Scholar]
  28. Kannel W. B. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995 Sep;18(3):181–196. doi: 10.1291/hypres.18.181. [DOI] [PubMed] [Google Scholar]
  29. Kannel W. B., Sorlie P., Castelli W. P., McGee D. Blood pressure and survival after myocardial infarction: the Framingham study. Am J Cardiol. 1980 Feb;45(2):326–330. doi: 10.1016/0002-9149(80)90654-2. [DOI] [PubMed] [Google Scholar]
  30. Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996 Jan 4;334(1):13–18. doi: 10.1056/NEJM199601043340103. [DOI] [PubMed] [Google Scholar]
  31. Kostis J. B. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995 Sep;8(9):909–914. doi: 10.1016/0895-7061(95)00156-j. [DOI] [PubMed] [Google Scholar]
  32. Lauer M. S., Anderson K. M., Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1991 Nov 1;18(5):1287–1294. doi: 10.1016/0735-1097(91)90549-o. [DOI] [PubMed] [Google Scholar]
  33. Lenfant C. Report of the Task Force on Research in Heart Failure. Circulation. 1994 Sep;90(3):1118–1123. doi: 10.1161/01.cir.90.3.1118. [DOI] [PubMed] [Google Scholar]
  34. Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990 May 31;322(22):1561–1566. doi: 10.1056/NEJM199005313222203. [DOI] [PubMed] [Google Scholar]
  35. Lew E. A. High blood pressure, other risk factors and longevity: the insurance viewpoint. Am J Med. 1973 Sep;55(3):281–294. doi: 10.1016/0002-9343(73)90130-7. [DOI] [PubMed] [Google Scholar]
  36. Liebson P. R., Grandits G. A., Dianzumba S., Prineas R. J., Grimm R. H., Jr, Neaton J. D., Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995 Feb 1;91(3):698–706. doi: 10.1161/01.cir.91.3.698. [DOI] [PubMed] [Google Scholar]
  37. Marantz P. R., Alderman M. H., Tobin J. N. Diagnostic heterogeneity in clinical trials for congestive heart failure. Ann Intern Med. 1988 Jul 1;109(1):55–61. doi: 10.7326/0003-4819-109-1-55. [DOI] [PubMed] [Google Scholar]
  38. Mensah G. A., Pappas T. W., Koren M. J., Ulin R. J., Laragh J. H., Devereux R. B. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993 Dec;11(12):1429–1440. doi: 10.1097/00004872-199312000-00016. [DOI] [PubMed] [Google Scholar]
  39. Motwani J. G., McAlpine H., Kennedy N., Struthers A. D. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet. 1993 May 1;341(8853):1109–1113. doi: 10.1016/0140-6736(93)93126-l. [DOI] [PubMed] [Google Scholar]
  40. Muiesan M. L., Salvetti M., Rizzoni D., Castellano M., Donato F., Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995 Oct;13(10):1091–1095. doi: 10.1097/00004872-199510000-00003. [DOI] [PubMed] [Google Scholar]
  41. Nakagawa O., Ogawa Y., Itoh H., Suga S., Komatsu Y., Kishimoto I., Nishino K., Yoshimasa T., Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995 Sep;96(3):1280–1287. doi: 10.1172/JCI118162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. PERERA G. A. Hypertensive vascular disease; description and natural history. J Chronic Dis. 1955 Jan;1(1):33–42. doi: 10.1016/0021-9681(55)90019-9. [DOI] [PubMed] [Google Scholar]
  43. Rabkin S. W., Mathewson F. A., Tate R. B. Prognosis after acute myocardial infarction: relation to blood pressure values before infarction in a prospective cardiovascular study. Am J Cardiol. 1977 Oct;40(4):604–610. doi: 10.1016/0002-9149(77)90077-7. [DOI] [PubMed] [Google Scholar]
  44. Sagie A., Larson M. G., Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med. 1993 Dec 23;329(26):1912–1917. doi: 10.1056/NEJM199312233292602. [DOI] [PubMed] [Google Scholar]
  45. Schachter M. Drug-induced modification of vascular structure: effects of antihypertensive drugs. Am Heart J. 1991 Jul;122(1 Pt 2):316–323. doi: 10.1016/0002-8703(91)90841-5. [DOI] [PubMed] [Google Scholar]
  46. Sever P., Beevers G., Bulpitt C., Lever A., Ramsay L., Reid J., Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993 Apr 10;306(6883):983–987. doi: 10.1136/bmj.306.6883.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Shumway N. E. Cardiac transplantation. J Am Coll Cardiol. 1993 Jul;22(1):6–7. doi: 10.1016/0735-1097(93)90809-f. [DOI] [PubMed] [Google Scholar]
  48. Sideris D. A., Toumanidis S. T., Kostis E. B., Diakos A., Moulopoulos S. D. Arrhythmogenic effect of high blood pressure: some observations on its mechanism. Cardiovasc Res. 1989 Nov;23(11):983–992. doi: 10.1093/cvr/23.11.983. [DOI] [PubMed] [Google Scholar]
  49. Struthers A. D. Prospects for using a blood sample in the diagnosis of heart failure. QJM. 1995 May;88(5):303–306. [PubMed] [Google Scholar]
  50. Swales J. D. The growth of medical science: the lessons of Malthus. J R Coll Physicians Lond. 1995 Nov-Dec;29(6):490–501. [PMC free article] [PubMed] [Google Scholar]
  51. Thybo N. K., Stephens N., Cooper A., Aalkjaer C., Heagerty A. M., Mulvany M. J. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995 Apr;25(4 Pt 1):474–481. doi: 10.1161/01.hyp.25.4.474. [DOI] [PubMed] [Google Scholar]
  52. Vasan R. S., Benjamin E. J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995 Dec;26(7):1565–1574. doi: 10.1016/0735-1097(95)00381-9. [DOI] [PubMed] [Google Scholar]
  53. Weber K. T., Brilla C. G., Cleland J. G., Cohn J. N., Hansson L., Heagerty A. M., Laragh J. H., Laurent S., Ollivier J. P., Pauletto P. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press. 1993 Mar;2(1):6–21. doi: 10.3109/08037059309077521. [DOI] [PubMed] [Google Scholar]
  54. Westerhof N., O'Rourke M. F. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens. 1995 Sep;13(9):943–952. doi: 10.1097/00004872-199509000-00002. [DOI] [PubMed] [Google Scholar]
  55. Yusuf S., Thom T., Abbott R. D. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension. 1989 May;13(5 Suppl):I74–I79. doi: 10.1161/01.hyp.13.5_suppl.i74. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES